Default

Allergy and immunology

Anaesthesia

Basic research

Cardiovascular medicine

Complementary medicine and alternative therapies

Critical care / intensive care

Dentistry / oral medicine

Dermatology

Emergency medicine

Endocrinology

Epidemiology

Ethics

Evidence-based medicine

Gastroenterology

Genetics

Geriatric medicine / aging

Haematology / blood transfusion

Health economics

Health policy

History of medicine

Infectious diseases

Internal medicine

Laboratory medicine

Medical education

Medical informatics

Neurology

Nursing

Nutrition and metabolism

Obstetrics and gynaecology

Occupational and environmental medicine

Oncology

Ophthalmology

Organisation of health care

Otolaryngology / head and neck surgery

Paediatrics

Palliative care

Pathology

Patient-physician relationship

Pharmacology and therapeutics

Primary care, family medicine

Psychiatry and psychotherapy

Psychosomatics

Public health

Quality of care

Radiology

Rehabilitation medicine

Renal medicine

Respiratory medicine

Rheumatology

Sexual medicine

Sports medicine

Statistics and research methods

Surgery

Transplantation

Travel medicine

Urology

Ops! No article found. Reset filter

Systematic review of pneumothoraces after endoscopic retrograde cholangiopancreatography

Systematic review
Lehmann V, Keller W, Egger B
Swiss Med Wkly. 2020;150:w20199

Pneumothoraces after endoscopic retrograde cholangiopancreatography (ERCP) are an uncommon but potentially lethal complication. Little evidence is available on their epidemiology, diagnosis and therapy.

Nonalcoholic fatty liver disease burden – Switzerland 2018–2030

Original article
Goossens N, Bellentani S, Cerny A, Dufour JF, Jornayvaz FR, Mertens J, Moriggia A, Muellhaupt B, Negro F, Razavi H, Semela D, Estes C
Swiss Med Wkly. 2019;149:w20152

As a result of epidemic levels of obesity and diabetes mellitus, nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) will contribute to increases in the liver-related disease burden in Switzerland.

Position statement on the use of biosimilars in inflammatory bowel disease

Review article: Biomedical intelligence
Burri E, Juillerat P, Maillard MH, Manz M, Michetti P, Mottet C, Rogler G, Zahnd N, Vavricka S
Swiss Med Wkly. 2019;149:w20148

A biosimilar is a biological medicine highly similar to another, already approved medicine. Physicians should be aware of definition, approval process, and biochemical and clinical features that distinguish biosimilars from the reference product.

Non-invasive diagnosis of liver steatosis: ready for primetime?

Viewpoint
Goossens N
Swiss Med Wkly. 2019;149:w20108

The formal diagnosis of hepatic steatosis relies on liver histology based on a liver biopsy, which is an invasive procedure that is not required in the majority of cases. Due to the high prevalence of liver steatosis, in particular in the context of an increase in NAFLD incidence, there has been renewed interest in use of non-invasive tools to assess the presence of liver disease.

Contrast-enhanced ultrasound (CEUS) has excellent diagnostic accuracy in differentiating focal liver lesions: results from a Swiss tertiary gastroenterological centre

Original article
Sawatzki M, Meyenberger C, Brand S, Semela D
Swiss Med Wkly. 2019;149:w20087

Focal liver lesions (FLLs) are common on conventional ultrasound. Contrast-enhanced ultrasound (CEUS) is highly accurate for differentiating benign and malignant FLLs, with an accuracy comparable to that of contrast-enhanced CT and MRI.

Controlled attenuation parameter for the assessment of liver steatosis in comparison with liver histology: a single-centre real life experience

Original article
Baumeler S, Jochum W, Neuweiler J, Bergamin I, Semela D
Swiss Med Wkly. 2019;149:w20077

Accurate diagnosis and staging of non-alcoholic fatty liver disease are essential for its management. Controlled attenuation parameter is a new noninvasive measurement made during transient elastography to assess liver steatosis.

Microelimination of chronic hepatitis C in Switzerland: modelling the Swiss Hepatitis Strategy goals in eastern, western and northern regions

Original article
Rusch U, Robbins S, Razavi H, Vernazza P, Blach S, Bruggmann P, Müllhaupt B, Negro F, Semela D
Swiss Med Wkly. 2019;149:w14694

The Swiss Hepatitis Strategy aims to eliminate hepatitis C virus infection and associated liver-related morbidity and mortality by 2030. To date, Little has been done to identify the epidemiology of HCV on the regional, or micro, level.

Hepatic manifestations of Wilson’s disease: 12-year experience in a Swiss tertiary referral centre

Original article
Vieira Barbosa J, Fraga M, Saldarriaga J, Hiroz P, Giostra E, Sempoux C, Ferenci P, Moradpour D
Swiss Med Wkly. 2018;148:w14699

Wilson’s disease is an inherited disorder of hepatic copper metabolism, leading to the accumulation of copper in the liver as well as the brain, cornea and other organs.

Genetics and epigenetics of inflammatory bowel disease

Review article: Biomedical intelligence
Wawrzyniak M, Scharl M
Swiss Med Wkly. 2018;148:w14671

Current knowledge about genetic and epigenetic involvement in the pathogenesis of inflammatory bowel disease is poor. In addition to genetic alterations, the intestinal microbiota and environmental factors also play a critical role.

A buyers’ club to improve access to hepatitis C treatment for vulnerable populations

Review article: Biomedical intelligence
Vernaz N, Calmy A, Hurst S, Jackson Y, Negro F, Perrier A, Wolff H
Swiss Med Wkly. 2018;148:w14649

High costs are an important barrier to treatment access for vulnerable and often uninsured patients with hepatitis C.

Verpassen Sie keinen Artikel!

close